Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from InflaRx ( (IFRX) ) is now available.
On June 26, 2025, InflaRx N.V. announced a change in its independent registered public accounting firm, transitioning from EY GmbH & Co. KG to KPMG AG Wirtschaftsprüfungsgesellschaft for the fiscal year ending December 31, 2025. This decision, approved by shareholders during the Annual General Meeting on April 24, 2025, was not due to any disagreements with EY, whose reports had been unqualified and without adverse opinions.
The most recent analyst rating on (IFRX) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on InflaRx stock, see the IFRX Stock Forecast page.
Spark’s Take on IFRX Stock
According to Spark, TipRanks’ AI Analyst, IFRX is a Underperform.
InflaRx’s stock score is primarily impacted by its weak financial performance, characterized by negative profitability and cash flow issues. Technical analysis supports a bearish outlook with poor market momentum. Valuation metrics further highlight concerns due to the company’s unprofitability.
To see Spark’s full report on IFRX stock, click here.
More about InflaRx
InflaRx N.V. operates in the biotechnology industry, focusing on developing anti-inflammatory therapeutics. The company is known for its work on monoclonal antibodies targeting the complement system, which plays a role in immune response.
Average Trading Volume: 479,926
Technical Sentiment Signal: Sell
Current Market Cap: $56.39M
Find detailed analytics on IFRX stock on TipRanks’ Stock Analysis page.